Trial Outcomes & Findings for A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia (NCT NCT02028455)

NCT ID: NCT02028455

Last Updated: 2025-08-27

Results Overview

The safety of the T cell infusion at the maximum tolerated dose determined in Phase 1, and further characterized in Phase 2, will be described

Recruitment status

ACTIVE_NOT_RECRUITING

Study phase

PHASE1/PHASE2

Target enrollment

167 participants

Primary outcome timeframe

Initial CAR T cell infusion through 30 days post infusion

Results posted on

2025-08-27

Participant Flow

Participant milestones

Participant milestones
Measure	Phase 1 - Cohort 1A This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^5 CAR T cells/kg	Phase 1 - Cohort 1B This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg	Phase 1 - Cohort 1C This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^6 CAR T cells/kg	Phase 1 - Cohort 1D This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^7 CAR T cells/kg	Phase 1 - Cohort 1F1 This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^5 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide	Phase 1 - Cohort 1F2 This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide	Phase 1- Not Treated Phase 1 subjects who were not treated	Phase 2 The phase 2 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1 x 10\^6 CAR T cells/kg following lymphodepletion if indicated.
Enrollment and Preliminary Assessments STARTED	7	12	7	5	6	6	4	120
Enrollment and Preliminary Assessments COMPLETED	7	12	7	5	6	6	0	103
Enrollment and Preliminary Assessments NOT COMPLETED	0	0	0	0	0	0	4	17
Treatment(T Cell Infusion) and Follow up STARTED	7	12	7	5	6	6	0	103
Treatment(T Cell Infusion) and Follow up COMPLETED	0	0	0	0	0	0	0	0
Treatment(T Cell Infusion) and Follow up NOT COMPLETED	7	12	7	5	6	6	0	103

Reasons for withdrawal

Reasons for withdrawal
Measure	Phase 1 - Cohort 1A This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^5 CAR T cells/kg	Phase 1 - Cohort 1B This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg	Phase 1 - Cohort 1C This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^6 CAR T cells/kg	Phase 1 - Cohort 1D This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^7 CAR T cells/kg	Phase 1 - Cohort 1F1 This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^5 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide	Phase 1 - Cohort 1F2 This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide	Phase 1- Not Treated Phase 1 subjects who were not treated	Phase 2 The phase 2 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1 x 10\^6 CAR T cells/kg following lymphodepletion if indicated.
Enrollment and Preliminary Assessments Went off study without receiving CAR T cell infusion	0	0	0	0	0	0	4	17
Treatment(T Cell Infusion) and Follow up Death	4	9	3	5	3	2	0	40
Treatment(T Cell Infusion) and Follow up Lost to Follow-up	0	0	0	0	0	1	0	2
Treatment(T Cell Infusion) and Follow up Still in long-term follow up	3	3	4	0	3	3	0	61

Baseline Characteristics

A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Phase 1-Cohort 1A n=7 Participants This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^5 CAR T cells/kg	Phase 1-Cohort 1B n=12 Participants This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg	Phase 1-Cohort 1C n=7 Participants This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^6 CAR T cells/kg	Phase 1-Cohort 1D n=5 Participants This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^7 CAR T cells/kg	Phase 1-Cohort 1F1 n=6 Participants This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^5 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide	Phase 1-Cohort 1F2 n=6 Participants This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide	Phase 1 - Not Treated n=4 Participants This phase 1 cohort did not receive Patient Derived CD19 specific CAR T cells	Phase 2 n=120 Participants The phase 2 cohort received Patient Derived CD19 specific CAR T cells following lymphodepletion if indicated	Total n=167 Participants Total of all reporting groups
Age, Continuous	19 years n=93 Participants	9 years n=4 Participants	15 years n=27 Participants	6 years n=483 Participants	10 years n=36 Participants	13.5 years n=10 Participants	11 years n=115 Participants	13 years n=40 Participants	13 years n=8 Participants
Sex: Female, Male Female	4 Participants n=93 Participants	3 Participants n=4 Participants	3 Participants n=27 Participants	5 Participants n=483 Participants	3 Participants n=36 Participants	4 Participants n=10 Participants	1 Participants n=115 Participants	40 Participants n=40 Participants	63 Participants n=8 Participants
Sex: Female, Male Male	3 Participants n=93 Participants	9 Participants n=4 Participants	4 Participants n=27 Participants	0 Participants n=483 Participants	3 Participants n=36 Participants	2 Participants n=10 Participants	3 Participants n=115 Participants	80 Participants n=40 Participants	104 Participants n=8 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	1 Participants n=93 Participants	4 Participants n=4 Participants	2 Participants n=27 Participants	2 Participants n=483 Participants	0 Participants n=36 Participants	1 Participants n=10 Participants	1 Participants n=115 Participants	38 Participants n=40 Participants	49 Participants n=8 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	6 Participants n=93 Participants	8 Participants n=4 Participants	5 Participants n=27 Participants	3 Participants n=483 Participants	5 Participants n=36 Participants	4 Participants n=10 Participants	2 Participants n=115 Participants	72 Participants n=40 Participants	105 Participants n=8 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	1 Participants n=36 Participants	1 Participants n=10 Participants	1 Participants n=115 Participants	10 Participants n=40 Participants	13 Participants n=8 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	0 Participants n=36 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=40 Participants	0 Participants n=8 Participants
Race (NIH/OMB) Asian	1 Participants n=93 Participants	0 Participants n=4 Participants	1 Participants n=27 Participants	1 Participants n=483 Participants	0 Participants n=36 Participants	1 Participants n=10 Participants	0 Participants n=115 Participants	6 Participants n=40 Participants	10 Participants n=8 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	0 Participants n=36 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	1 Participants n=40 Participants	1 Participants n=8 Participants
Race (NIH/OMB) Black or African American	0 Participants n=93 Participants	1 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	0 Participants n=36 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	4 Participants n=40 Participants	5 Participants n=8 Participants
Race (NIH/OMB) White	5 Participants n=93 Participants	8 Participants n=4 Participants	4 Participants n=27 Participants	2 Participants n=483 Participants	5 Participants n=36 Participants	3 Participants n=10 Participants	3 Participants n=115 Participants	66 Participants n=40 Participants	96 Participants n=8 Participants
Race (NIH/OMB) More than one race	0 Participants n=93 Participants	1 Participants n=4 Participants	1 Participants n=27 Participants	0 Participants n=483 Participants	0 Participants n=36 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	4 Participants n=40 Participants	6 Participants n=8 Participants
Race (NIH/OMB) Unknown or Not Reported	1 Participants n=93 Participants	2 Participants n=4 Participants	1 Participants n=27 Participants	2 Participants n=483 Participants	1 Participants n=36 Participants	2 Participants n=10 Participants	1 Participants n=115 Participants	39 Participants n=40 Participants	49 Participants n=8 Participants
Diagnosis Leukemia	7 Participants n=93 Participants	12 Participants n=4 Participants	7 Participants n=27 Participants	5 Participants n=483 Participants	6 Participants n=36 Participants	6 Participants n=10 Participants	4 Participants n=115 Participants	106 Participants n=40 Participants	153 Participants n=8 Participants
Diagnosis Non Hodgkin's Lymphoma	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	0 Participants n=36 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	14 Participants n=40 Participants	14 Participants n=8 Participants

PRIMARY outcome

Timeframe: Initial CAR T cell infusion through 30 days post infusion

Population: Phase 1 cohorts: Toxicity-evaluable leukemia patients who received CAR T cells; Phase 2 cohort: Toxicity-evaluable leukemia patients treated with the Phase 2 dose, 1 x 10\^6 CAR T cells/kg, following lymphodepletion with fludarabine and cyclophosphamide

The safety of the T cell infusion at the maximum tolerated dose determined in Phase 1, and further characterized in Phase 2, will be described

Outcome measures

Outcome measures
Measure	Phase 1 - Cohort 1A n=7 Participants This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^5 CAR T cells/kg	Phase 1-Cohort 1B n=12 Participants This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg	Phase 1-Cohort 1C n=7 Participants This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^6 CAR T cells/kg	Phase 1-Cohort 1D n=5 Participants This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^7 CAR T cells/kg	Phase 1-Cohort 1F1 n=6 Participants This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^5 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide	Phase 1-Cohort 1F2 n=6 Participants This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide	Phase 2 n=81 Participants The phase 2 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1 x 10\^6 CAR T cells/kg following lymphodepletion if indicated	Phase 2 The phase 2 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg following lymphodepletion if indicated
Number of Participants Who Experienced an Adverse Event Meeting the Dose-Limiting Toxicity Definition Number of participants who experienced an AE meeting the Dose-Limiting Toxicity definition	1 Participants	1 Participants	2 Participants	2 Participants	0 Participants	1 Participants	17 Participants	—
Number of Participants Who Experienced an Adverse Event Meeting the Dose-Limiting Toxicity Definition Number of participants who did not experience an AE meeting the Dose-Limiting Toxicity definition	6 Participants	11 Participants	5 Participants	3 Participants	6 Participants	5 Participants	64 Participants	—

PRIMARY outcome

Timeframe: Initial CAR T cell infusion through Day 63 post infusion assessment (+/- 14 days)

Population: Efficacy-evaluable leukemia patients in Phase 2, plus Phase 1 patients treated at the Phase 2 dose in cohort 1F2, who received SCRIv1 or SCRIv1.5 CAR T cells following prescribed lymphodepletion with fludarabine and cyclophosphamide

The efficacy of the T cell infusion will be estimated based on the number of participants who have an MRD negative bone marrow aspirate following the initial T cell infusion

Outcome measures

Outcome measures
Measure	Phase 1 - Cohort 1A n=71 Participants This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^5 CAR T cells/kg	Phase 1-Cohort 1B This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg	Phase 1-Cohort 1C This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^6 CAR T cells/kg	Phase 1-Cohort 1D This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^7 CAR T cells/kg	Phase 1-Cohort 1F1 This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^5 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide	Phase 1-Cohort 1F2 This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide	Phase 2 The phase 2 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1 x 10\^6 CAR T cells/kg following lymphodepletion if indicated	Phase 2 The phase 2 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg following lymphodepletion if indicated
Number of Participants With an MRD Negative Complete Remission After Initial CAR T Cell Infusion Number of Participants with an MRD Negative Complete Remission after Initial CAR T Infusion	63 Participants	—	—	—	—	—	—	—
Number of Participants With an MRD Negative Complete Remission After Initial CAR T Cell Infusion Number of Participants without an MRD Negative Complete Remission after Initial CAR T Infusion	8 Participants	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Up to 28 days per manufacturing attempt

Population: Participants evaluable for manufacturing feasibility.

The feasibility of manufacturing and releasing T cell products from pediatric and young adult patients with CD19+ relapsed or refractory leukemia

Outcome measures

Outcome measures
Measure	Phase 1 - Cohort 1A n=7 Participants This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^5 CAR T cells/kg	Phase 1-Cohort 1B n=12 Participants This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg	Phase 1-Cohort 1C n=7 Participants This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^6 CAR T cells/kg	Phase 1-Cohort 1D n=5 Participants This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^7 CAR T cells/kg	Phase 1-Cohort 1F1 n=6 Participants This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^5 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide	Phase 1-Cohort 1F2 n=6 Participants This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide	Phase 2 n=3 Participants The phase 2 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1 x 10\^6 CAR T cells/kg following lymphodepletion if indicated	Phase 2 n=119 Participants The phase 2 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg following lymphodepletion if indicated
Number of Participants Who Have a Releasable Cell Product Generated Number of participants for whom a releasable CAR T cell product was manufactured	7 Participants	12 Participants	7 Participants	5 Participants	6 Participants	6 Participants	1 Participants	116 Participants
Number of Participants Who Have a Releasable Cell Product Generated Number of participants for whom no releasable CAR T cell product was manufactured	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	2 Participants	3 Participants

SECONDARY outcome

Timeframe: Initial CAR T Infusion through Day 63 post infusion assessment (+/- 14 days)

Population: Efficacy-evaluable leukemia patients in Phase 2, plus Phase 1 patients treated at the Phase 2 dose in Cohort 1F2, who received SCRIv1 or SCRIv1.5 CAR T cells following prescribed lymphodepletion with fludarabine and cyclophosphamide and who were followed for loss of persistence through the Day 63 assessment window. Excludes one participant with insufficient samples collected to determine Day 63 persistence status.

Participants will be followed for 63 days to determine if the transferred T cells remain detectable in the blood and bone marrow

Outcome measures

Outcome measures
Measure	Phase 1 - Cohort 1A n=70 Participants This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^5 CAR T cells/kg	Phase 1-Cohort 1B This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg	Phase 1-Cohort 1C This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^6 CAR T cells/kg	Phase 1-Cohort 1D This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^7 CAR T cells/kg	Phase 1-Cohort 1F1 This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^5 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide	Phase 1-Cohort 1F2 This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide	Phase 2 The phase 2 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1 x 10\^6 CAR T cells/kg following lymphodepletion if indicated	Phase 2 The phase 2 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg following lymphodepletion if indicated
Persistence of Functional CD19 CAR+ T Cells Number of participants with functional CAR T cell persistence through the Day 63 study assessment	42 Participants	—	—	—	—	—	—	—
Persistence of Functional CD19 CAR+ T Cells Number of participants without functional CAR T cell persistence through the Day 63 study assessment	28 Participants	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Initial CAR T Infusion through Day 63 post infusion assessment (+/- 14 days)

Population: Number of participants with a history of prior allogeneic HSCT (hematopoietic stem cell transplantation) who received CAR T infusion

Outcome measures

Outcome measures
Measure	Phase 1 - Cohort 1A n=7 Participants This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^5 CAR T cells/kg	Phase 1-Cohort 1B n=7 Participants This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg	Phase 1-Cohort 1C n=4 Participants This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^6 CAR T cells/kg	Phase 1-Cohort 1D n=3 Participants This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^7 CAR T cells/kg	Phase 1-Cohort 1F1 n=4 Participants This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^5 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide	Phase 1-Cohort 1F2 n=3 Participants This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide	Phase 2 n=36 Participants The phase 2 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1 x 10\^6 CAR T cells/kg following lymphodepletion if indicated	Phase 2 The phase 2 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg following lymphodepletion if indicated
Number of Participants With Recrudescence or Development of Acute GVHD (Graft Versus Host Disease) Symptoms Post CAR T Infusion Number of subjects without recrudescence or development of Acute GVHD symptoms post CAR T infusion	6 Participants	7 Participants	4 Participants	3 Participants	4 Participants	3 Participants	36 Participants	—
Number of Participants With Recrudescence or Development of Acute GVHD (Graft Versus Host Disease) Symptoms Post CAR T Infusion Number of subjects with recrudescence or development of Acute GVHD symptoms post CAR T infusion	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—

SECONDARY outcome

Timeframe: 3 years

Population: Number of subjects receiving cetuximab on study for ablation of CAR T cells

The efficacy of cetuximab to ablate the T cells will be measured by loss of detection of T cells and any associated toxicities as well as facilitating B cell recovery.

Outcome measures

Outcome measures
Measure	Phase 1 - Cohort 1A This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^5 CAR T cells/kg	Phase 1-Cohort 1B This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg	Phase 1-Cohort 1C This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^6 CAR T cells/kg	Phase 1-Cohort 1D This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^7 CAR T cells/kg	Phase 1-Cohort 1F1 This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\^5 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide	Phase 1-Cohort 1F2 This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide	Phase 2 n=2 Participants The phase 2 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1 x 10\^6 CAR T cells/kg following lymphodepletion if indicated	Phase 2 The phase 2 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg following lymphodepletion if indicated
Number of Participants That Received Cetuximab Who Have T Cells Successfully Ablated Number of participants whose CAR T cells were successfully ablated by cetuximab administration	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—
Number of Participants That Received Cetuximab Who Have T Cells Successfully Ablated Number of participants receiving cetuximab on study for ablation of CAR T cells	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	2 Participants	—

Adverse Events

Phase 1 - Cohort 1A

Serious events: 6 serious events

Other events: 7 other events

Deaths: 4 deaths

Phase 1 - Cohort 1B

Serious events: 10 serious events

Other events: 12 other events

Deaths: 9 deaths

Phase 1 - Cohort 1C

Serious events: 5 serious events

Other events: 7 other events

Deaths: 3 deaths

Phase 1 - Cohort 1D

Serious events: 5 serious events

Other events: 5 other events

Deaths: 5 deaths

Phase 1 - Cohort 1F1

Serious events: 2 serious events

Other events: 6 other events

Deaths: 3 deaths

Phase 1 - Cohort 1F2

Serious events: 4 serious events

Other events: 6 other events

Deaths: 2 deaths

Phase 2

Serious events: 48 serious events

Other events: 103 other events

Deaths: 40 deaths

Serious adverse events

Serious adverse events
Measure	Phase 1 - Cohort 1A n=7 participants at risk This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 5x10\^5 CAR T cells/kg	Phase 1 - Cohort 1B n=12 participants at risk This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg	Phase 1 - Cohort 1C n=7 participants at risk This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 5x10\^6 CAR T cells/kg	Phase 1 - Cohort 1D n=5 participants at risk This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 1x10\^7 CAR T cells/kg	Phase 1 - Cohort 1F1 n=6 participants at risk This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 5x10\^5 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide	Phase 1 - Cohort 1F2 n=6 participants at risk This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide	Phase 2 n=103 participants at risk The phase 2 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 1 x 10\^6 CAR T cells/kg following lymphodepletion if indicated
Blood and lymphatic system disorders Febrile Neutropenia	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Cardiac disorders Atrial Fibrillation	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Cardiac disorders Cardiac Arrest	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	1.9% 2/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Cardiac disorders Heart Failure	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Cardiac disorders Left Ventricular Systolic Dysfunction	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	20.0% 1/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Cardiac disorders Pericardial Tamponade	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Endocrine disorders Adrenal Insufficiency	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Eye disorders Optic Nerve Disorder	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Eye disorders Retinopathy	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Gastrointestinal disorders Colitis	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Gastrointestinal disorders Nausea	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Gastrointestinal disorders Pancreatitis	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Gastrointestinal disorders Typhlitis	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	20.0% 1/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Gastrointestinal disorders Vomiting	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
General disorders Fever	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	2.9% 3/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Immune system disorders Anaphylaxis	28.6% 2/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Immune system disorders Cytokine Release Syndrome	28.6% 2/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	41.7% 5/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	71.4% 5/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	60.0% 3/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	50.0% 3/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	21.4% 22/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Infections and infestations Appendicitis	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Infections and infestations Catheter Related Infection	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	33.3% 4/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	60.0% 3/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Infections and infestations Gram-Positive Bacterial Infection	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Infections and infestations Lung Infection	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Infections and infestations Periorbital Infection	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Infections and infestations Sepsis	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	2.9% 3/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Infections and infestations Skin Infection	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Infections and infestations Yeast Infection	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Injury, poisoning and procedural complications Infusion Related Reaction	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Investigations Blood Bilirubin Increased	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	20.0% 1/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Investigations Creatinine Increased	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Investigations Neutrophil Count Decreased	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Metabolism and nutrition disorders Acidosis	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Metabolism and nutrition disorders Dehydration	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Metabolism and nutrition disorders Hyperglycemia	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Metabolism and nutrition disorders Hyponatremia	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Metabolism and nutrition disorders Hypophosphatemia	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Musculoskeletal and connective tissue disorders Bone Pain	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Musculoskeletal and connective tissue disorders Jaw Pain	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Progressive Leukemia	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Nervous system disorders Aphasia	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Nervous system disorders Edema Cerebral	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	1.9% 2/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Nervous system disorders Encephalopathy	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	33.3% 4/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	42.9% 3/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	60.0% 3/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	33.3% 2/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	11.7% 12/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Nervous system disorders Hydrocephalus	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Nervous system disorders Intracranial Hemorrhage	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Nervous system disorders Leukoencephalopathy	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Nervous system disorders Nystagmus	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Nervous system disorders Seizure	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	28.6% 2/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	20.0% 1/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	6.8% 7/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Psychiatric disorders Confusion	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	1.9% 2/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Psychiatric disorders Delirium	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Psychiatric disorders Hallucinations	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Psychiatric disorders Psychosis	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Renal and urinary disorders Acute Kidney Injury	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Respiratory, thoracic and mediastinal disorders Adult Respiratory Distress Syndrome	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	2.9% 3/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Respiratory, thoracic and mediastinal disorders Laryngeal Obstruction	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Respiratory, thoracic and mediastinal disorders Respiratory Failure	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	2.9% 3/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Vascular disorders Capillary Leak Syndrome	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	20.0% 1/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	1.9% 2/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Vascular disorders Hypotension	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.

Other adverse events

Other adverse events
Measure	Phase 1 - Cohort 1A n=7 participants at risk This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 5x10\^5 CAR T cells/kg	Phase 1 - Cohort 1B n=12 participants at risk This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg	Phase 1 - Cohort 1C n=7 participants at risk This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 5x10\^6 CAR T cells/kg	Phase 1 - Cohort 1D n=5 participants at risk This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 1x10\^7 CAR T cells/kg	Phase 1 - Cohort 1F1 n=6 participants at risk This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 5x10\^5 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide	Phase 1 - Cohort 1F2 n=6 participants at risk This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 1x10\^6 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide	Phase 2 n=103 participants at risk The phase 2 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 1 x 10\^6 CAR T cells/kg following lymphodepletion if indicated
Blood and lymphatic system disorders Anemia	57.1% 4/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	91.7% 11/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	85.7% 6/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	80.0% 4/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	83.3% 5/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	50.0% 3/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	58.3% 60/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Blood and lymphatic system disorders Disseminated Intravascular Coagulation	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	66.7% 8/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	57.1% 4/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	40.0% 2/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	83.3% 5/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	33.3% 2/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	14.6% 15/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Blood and lymphatic system disorders Febrile Neutropenia	100.0% 7/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	83.3% 10/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	85.7% 6/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	20.0% 1/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	83.3% 5/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	66.7% 4/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	35.0% 36/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Blood and lymphatic system disorders Leukocytosis	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Cardiac disorders Sinus Tachycardia	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	25.0% 3/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	2.9% 3/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Ear and labyrinth disorders Ear Pain	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Eye disorders Optic Nerve Disorder	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Gastrointestinal disorders Abdominal Pain	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 2/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	7.8% 8/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Gastrointestinal disorders Constipation	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	20.0% 1/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Gastrointestinal disorders Diarrhea	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	25.0% 3/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	40.0% 2/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	7.8% 8/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Gastrointestinal disorders Gastroparesis	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Gastrointestinal disorders Ileus	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Gastrointestinal disorders Nausea	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	33.3% 4/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	40.0% 2/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.5% 17/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Gastrointestinal disorders Oral Pain	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Gastrointestinal disorders Perirectal Pain	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	20.0% 1/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Gastrointestinal disorders Rectal Pain	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	20.0% 1/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	1.9% 2/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Gastrointestinal disorders Vomiting	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 2/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	60.0% 3/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	10.7% 11/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
General disorders Chills	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	1.9% 2/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
General disorders Fatigue	28.6% 2/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	1.9% 2/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
General disorders Fever	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	5.8% 6/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
General disorders Malaise	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
General disorders Non-Cardiac Chest Pain	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
General disorders Pain	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 2/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	9.7% 10/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Immune system disorders Allergic Reaction	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	1.9% 2/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Immune system disorders Cytokine Release Syndrome	57.1% 4/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	58.3% 7/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	40.0% 2/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	83.3% 5/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	33.3% 2/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	66.0% 68/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Immune system disorders Igg Decreased	28.6% 2/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	20.0% 1/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	5.8% 6/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Infections and infestations Catheter Related Infection	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	4.9% 5/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Infections and infestations Enterocolitis Infectious	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Infections and infestations Mucosal Infection	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 2/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	1.9% 2/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Infections and infestations Nail Infection	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Infections and infestations Sinusitis	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Infections and infestations Skin Infection	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	3.9% 4/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Infections and infestations Upper Respiratory Infection	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 2/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	3.9% 4/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Injury, poisoning and procedural complications Hip Fracture	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Injury, poisoning and procedural complications Spinal Fracture	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Investigations Activated Partial Thromboplastin Time Prolonged	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	11.7% 12/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Investigations Alanine Aminotransferase Increased	28.6% 2/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 2/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	28.6% 2/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	9.7% 10/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Investigations Aspartate Aminotransferase Increased	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	20.0% 1/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	7.8% 8/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Investigations Blood Bilirubin Increased	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 2/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	11.7% 12/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Investigations Creatinine Increased	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	25.0% 3/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	1.9% 2/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Investigations Electrocardiogram Qt Corrected Interval Prolonged	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	20.0% 1/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Investigations Fibrinogen Decreased	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	6.8% 7/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Investigations Lymphocyte Count Decreased	28.6% 2/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	41.7% 5/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	42.9% 3/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	20.0% 1/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	19.4% 20/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Investigations Neutrophil Count Decreased	71.4% 5/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	58.3% 7/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	85.7% 6/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	60.0% 3/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	66.7% 4/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	83.3% 5/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	53.4% 55/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Investigations Platelet Count Decreased	71.4% 5/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	66.7% 8/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	57.1% 4/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	80.0% 4/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	66.7% 4/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	40.8% 42/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Investigations Urine Output Decreased	28.6% 2/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	41.7% 5/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	28.6% 2/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	60.0% 3/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Investigations Weight Gain	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	33.3% 4/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	2.9% 3/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Investigations Weight Loss	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	28.6% 2/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	20.0% 1/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	3.9% 4/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Investigations White Blood Cell Decreased	71.4% 5/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	66.7% 8/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	85.7% 6/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	20.0% 1/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	50.0% 3/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	66.7% 4/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	44.7% 46/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Metabolism and nutrition disorders Anorexia	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	50.0% 6/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	12.6% 13/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Metabolism and nutrition disorders Hyperglycemia	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	20.0% 1/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	5.8% 6/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Metabolism and nutrition disorders Hypernatremia	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	20.0% 1/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	6.8% 7/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Metabolism and nutrition disorders Hypertriglyceridemia	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	60.0% 3/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	2.9% 3/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Metabolism and nutrition disorders Hypoalbuminemia	42.9% 3/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 2/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	40.0% 2/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.7% 9/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Metabolism and nutrition disorders Hypocalcemia	57.1% 4/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	50.0% 6/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	28.6% 2/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	80.0% 4/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	10.7% 11/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Metabolism and nutrition disorders Hypokalemia	28.6% 2/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	33.3% 4/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	28.6% 2/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	80.0% 4/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	11.7% 12/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Metabolism and nutrition disorders Hypomagnesemia	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Metabolism and nutrition disorders Hyponatremia	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 2/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	2.9% 3/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Metabolism and nutrition disorders Hypophosphatemia	28.6% 2/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	50.0% 6/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	80.0% 4/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	13.6% 14/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Musculoskeletal and connective tissue disorders Back Pain	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	28.6% 2/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	3.9% 4/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Musculoskeletal and connective tissue disorders Joint Pain	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Musculoskeletal and connective tissue disorders Pain In Extremity	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 2/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	4.9% 5/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Musculoskeletal and connective tissue disorders Pain-Left Side	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Musculoskeletal and connective tissue disorders Shoulder Pain	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Nervous system disorders Dizziness	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	2.9% 3/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Nervous system disorders Dysarthria	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Nervous system disorders Encephalopathy	28.6% 2/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	20.0% 1/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.7% 9/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Nervous system disorders Headache	71.4% 5/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 2/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	42.9% 3/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	20.0% 1/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	50.0% 3/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	31.1% 32/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Nervous system disorders Neuropathic Pain	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Nervous system disorders Peripheral Sensory Neuropathy	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.97% 1/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Nervous system disorders Sensory Neuropathy	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Nervous system disorders Tremor	28.6% 2/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	20.0% 1/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	33.3% 2/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.5% 17/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Psychiatric disorders Anxiety	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	1.9% 2/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Psychiatric disorders Confusion	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	20.0% 1/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	33.3% 2/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	12.6% 13/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Psychiatric disorders Depression	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	20.0% 1/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Psychiatric disorders Hypomania	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Psychiatric disorders Insomnia	28.6% 2/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	20.0% 1/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	2.9% 3/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Psychiatric disorders Nightmares	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Renal and urinary disorders Polydipsia	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Renal and urinary disorders Polyuria	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Reproductive system and breast disorders Vaginal Pain	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	20.0% 1/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 2/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	5.8% 6/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Respiratory, thoracic and mediastinal disorders Pleural Effusion	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Skin and subcutaneous tissue disorders Fungal Diaper Rash	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	1.9% 2/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Skin and subcutaneous tissue disorders Skin GVHD	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Skin and subcutaneous tissue disorders Skin Ulceration	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Vascular disorders Capillary Leak Syndrome	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	8.3% 1/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	20.0% 1/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	1.9% 2/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Vascular disorders Hypertension	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	58.3% 7/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	28.6% 2/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	60.0% 3/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	33.3% 2/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	9.7% 10/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.
Vascular disorders Hypotension	14.3% 1/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	33.3% 4/12 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	0.00% 0/7 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	20.0% 1/5 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	16.7% 1/6 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.	6.8% 7/103 • All adverse event data are systematically collected from initiation of infusion through 30 days post CAR T infusion. Serious Adverse Event reports with an attribution of Possibly, Probably or Definitely related to CAR T cells are included in the data up to 1 year post-infusion. Adverse events were assessed using NCI Common Terminology Criteria for Adverse Events v4.0, except for Cytokine Release Syndrome during Phase 2, which was assessed using modified Lee criteria.\* Neurotoxicity and CRS events with grade \>=1 and other events with grade \>=2 were systematically captured \*Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95.

Additional Information

Dr. Colleen Annesley

Seattle Children's Therapeutics

Phone: 206-987-7122

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place